Kornimate/medical-research-clean huggingface dataset:
a comparison of balloon catheter versus ocytocin for cervical ripening on scarred uterus with unfavorable cervix

Conditions: Scarred Uterus

Summary: increasing cesarean rate in france is worrying. different methods are described for ripening labor : the use of prostaglandins is described but maybe dangerous for patients with scarred uterus and is not recommended. intracervical balloon is an efficient alternative methods which as already been tested for unfavorable cervix ripening on nulliparous women. but it was rarely tested on women with scared uterus and unfavorable cervix (bishop score \<4). the investigators propose a prospective randomised trial comparing cervix ripening with intracervical balloon inflated by 50 ml sterile water during 12 hours versus ocytocin (reference method). the investigators expect to demonstrate what it's a safe method to increase vaginal delivery for women with previous cesarean section who need an induction of labour.


Eligibility criteria:
inclusion criteria: * pregnancy over 37 weeks * singleton pregnancy * vertex presentation * previous caesarean section with unique transversal segmentary incision * medical indication of induction of labor * unfavorable cervix with bishop score \< 4 * no premature rupture of membranes * informed consent exclusion criteria: * before 18 years old * placenta praevia * premature rupture of membranes * uterine scar other than transversal segmentary incision * cervical infection (except streptoccoccus agalactiae carrier) or choriamnionitis * multiple pregnancy * fetal malpresentation * cesarean indication * latex allergy * no informed consent
study of men with mild to moderate erectile dysfunction to evaluate the efficacy of viagra 8 hours post-dose

Conditions: Impotence

Summary: safety/efficacy of 100mg viagra at 8 hours post dose in men with mild to moderate erectile dysfunction


Eligibility criteria:
inclusion criteria: * men 18-70 years of age * documented clinical diagnosis of erectile dysfunction of at least 3 months duration. exclusion criteria: * subjects with penile implants * subjects with a known history of retinitis pigmentosa. * subjects, due to the requirement of 100 mg dosage, who are receiving concomitant treatment with the potent cyp3a4 inhibitor ritonavir.
effect of cuff pressure during operation on postoperative sore throat

Conditions: Arthroplasty, Replacement, Hip

Summary: when general anesthesia is performed for surgery, tracheal intubation is performed. in order to ventilate after performing tracheal intubation, air is injected into the cuff attached to the tube to fill the gap between the tracheal tube and the patients's inner surface of trachea. even though, 20 to 30 cm h2o is known to be the appropriate pressure to prevent air leaks while preventing ischemic damage of tracheal mucosa. so, researchers want to observe clinical differences in pressure at both ends of the safety zone of the cuff pressure.

patients who are scheduled for elective surgery/ general anesthesia are randomized to two groups. l : cuff pressure - 20cmh2o ll : cuff pressure - 30cmh2o after tracheal intubation with routine method, cuff pressure is continuously monitored with manometer. the anesthesia during surgery is maintained with 0.8 mac of desflurane and continuous remifentanil. clinical outcomes (sore throat, hoarseness and postoperative pain) are evaluated after 0 minutes, 2 hours, 4 hours, and 24 hours after surgery.

Eligibility criteria:
inclusion criteria: * patients undergoing total hip replacement arthroplasty that require general anesthesia exclusion criteria: * a patient who disagrees with the study * tracheal stenosis * operation time \> 3 hours or \< 1 hour 30 minutes * difficult airway * drug abuse, alcoholism
measurement of circulating cell-free dna (cfdna) for diagnosis and prognosis of various diseases and evaluation of tissue damage

Conditions: Correlation of cFDNA During CPB to Laboratories SIRS Parameters and Clinical Outcomes

Summary: to characterize the changes in circulating cell-free dna (cfdna) levels during cardiopulmonary bypass (cpb) and to access their association with outcomes compared to standard scores.

in a prospective study, the investigators enrolled seventy-one consecutive patients undergoing non-emergent coronary artery bypass grafting. blood was drawn at baseline, after 20 and 40 minutes on cpb, after cross-clamp removal, and 30 minutes after chest closure. cfdna was measured in sera by fluorescent method. the investigators hypothesize that cfdna measured by will reflect the magnitude of inflammation induced by cpb. thus, these measurements could serve for the real-time prognosis of patients undergoing cardiac surgery. the investigators correlate cfdna to laboratories and clinical outcomes.

Eligibility criteria:
inclusion criteria: * elective coronary artery bypass grafting surgery exclusion criteria: * age \< 18 * non elective surgery * other than cabg surgery * redo cabg

Keywords: cfdna-circulating cell-free dna cpb-cardiopulmonary bypass sirs-systemic inflammatory response syndrome
studies on tumors of the thyroid

Conditions: Hurthle Cell Thyroid Cancer; Tall Cell Variant Thyroid Cancer; Follicular Thyroid Cancer; Thyroid Cancer; Papillary Thyroid Cancer

Summary: participants in this study will be patients diagnosed with or suspected to have a thyroid nodule or thyroid cancer. the main purpose of this study is to further understand the methods for the diagnosis and treatment of thyroid nodules and thyroid cancer. many of the test performed are in the context of standard medical care that is offered to all patients with thyroid nodules or thyroid cancer. other tests are performed for research purposes. in addition, blood and tissue samples will be taken for research and genetic studies.

the purpose of this study is to gain knowledge and experience in the diagnosis and therapy of thyroid cancer using established best standard of care and new techniques and approaches as they are developed. study subjects will include adults and children with thyroid nodules requiring diagnostic imaging and fine needle aspiration biopsy, surgery, radioiodine scanning or therapy, appropriate follow up, consisting of tumor markers monitoring and anatomical and functional imaging. the limitations and significance of serum thyroglobulin (tg) measurement for diagnosing tumor recurrence will be assessed. the study will permit a continued evaluation of the risk/benefit ratio of already established methods of administering radioiodine therapy, including the impact of pre-treatment dosimetric calculations, individualizing treatment with radioiodine. under this protocol, samples of benign nodules and cancer tissue specimens for research studies will be collected. data and samples collected during routine clinical care will be used to address research questions utilizing a number of approaches including microscopy, immunohistochemistry, proteomics and molecular analysis. all research studies will relate to the diagnosis, natural history and therapy of thyroid tumors, regulation of thyroid function, and the effects of thyroid function on the body. blood and urine specimens will be collected for research studies in both the hypothyroid and euthyroid state.

Eligibility criteria:
* inclusion criteria: in order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. male or female, adults or children \>= 6 months+. 2. patients with known or suspected thyroid nodules and/or thyroid cancer. 3. at risk family members of patients who have a genetic susceptibility to developing thyroid cancer. exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: 1. serious underlying medical conditions that restrict diagnostic testing or therapy such as renal failure, congestive cardiac failure or active coexisting non-thyroid carcinoma requiring intervention before thyroid cancer is addressed.

Keywords: thyroid fine needle biopsy radioiodine dosimetry natural history
work activity augmented by cognitive rehabilitation for schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: this research investigates the benefits of productive activity and cognitive rehabilitation for patients with schizophrenia. key questions are: 1. does cognitive rehabilitation plus work activity produce better outcomes than work activity alone? 2. is cognitive rehabilitation more helpful for individuals with moderate or greater cognitive impairment than for individuals without such impairment? 3. does cognitive rehabilitation reduce the dropout rate and increase participation in work activity for cognitively impaired subjects? 4. what features of cognitive rehabilitation are most important for clinical and rehabilitation outcomes?

this is a randomized, matching study in which subjects are stratified by degree of cognitive impairment, then randomly assigned to one of two conditions: work services only vs. work services plus cognitive rehabilitation. longitudinal analysis of work activity, work performance, symptoms, quality of life, cognitive function and service utilization are made.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia or schizoaffective disorder exclusion criteria: * change in psychiatric medications or housing within 30 days of study intake * episode of drug abuse within 30 days of study intake * gaf score 30 or less * known neurological disease or developmental disability

Keywords: work therapy cognitive rehabilitation schizophrenia schizoaffective disorder treatment outcome
ability of aprepitant to block opioid reward in non-dependent opiate abusers

Conditions: Opioid-Related Disorders; Heroin Dependence; Substance-Related Disorders

Summary: the objective of this study is to determine whether aprepitant blocks the opiate reward system in non-dependent opiate abusers, indicating its potential as a safe, non-addictive first line therapy for early heroin abuse.

this initial proof-of-concept study focuses on evaluating whether an nk1 antagonist, aprepitant, can block opiate reward in non-dependent opiate experienced volunteers in response to a standard opiate challenge. sixty subjects will be included in a randomized controlled study. following a training challenge session, they will receive 1 week treatment with aprepitant or matching placebo, followed by a challenge session during which subjective and physiological responses to the opiate partial agonist buprenorphine will be assessed.

Eligibility criteria:
inclusion criteria: * age 18 - 50 * current opiate use, without dependence exclusion criteria: * clinical diagnosis of opiate dependence * positive urine screen for opiates on day of challenge sessions * meet diagnostic criteria for any other substance abuse disorder except nicotine within the last 12 months. * any ongoing prescription medication other than oral contraceptives or hormone replacement * any serious medical condition which in the judgment of the investigators makes administration of opiates medically inappropriate.

Keywords: heroin abuse opioids opiates substance abuse addiction
the effect of two dıfferent technıques used in psychomotor skılls traınıng on nursıng students

Conditions: Anxiety; Clinical Decision-making; Simulation Training; Nursing Students

Summary: background: nursing education aims to provide students with knowledge and skills related to the profession and develop students in terms of personal characteristics such as clinical decision-making, problem-solving, and critical thinking. innovative approaches and interactive learning strategies are needed during education periods to increase skills and personal development. aim: the study aimed to investigate the effect of computer simulation and imagery learning techniques in psychomotor skills training of nursing students on self-confidence and anxiety in clinical decision-making and academic achievement. design: it is an experimental study with a pretest-posttest design with two intervention groups. setting: the study was conducted between december 2023 and january 2024 at the faculty of health sciences of a university in turkey's central region.

background: nursing education aims to provide students with knowledge and skills related to the profession and develop students in terms of personal characteristics such as clinical decision-making, problem-solving, and critical thinking. innovative approaches and interactive learning strategies are needed during education periods to increase skills and personal development. aim: the study aimed to investigate the effect of computer simulation and imagery learning techniques in psychomotor skills training of nursing students on self-confidence and anxiety in clinical decision-making and academic achievement. design: it is an experimental study with a pretest-posttest design with two intervention groups. setting: the study was conducted between december 2023 and january 2024 at the faculty of health sciences of a university in turkey's central region. methods: the turkish version of the "self-confidence and anxiety in clinical decision making" scale was used at the beginning (pre-test) and end (post-test) of the four-week sessions of the interventions. moreover, the "academic achievement test" was used at the end of the interventions. differences in mean scores between the groups were analyzed with mixed-design anova.

Eligibility criteria:
inclusion criteria: * taking the fundamentals of nursing course for the first time, * being have to attend to the fundamentals of nursing course, * having a gpa above 1.80, * volunteering to participate in the study. it was determined that there were 96 students enrolled in the fundamentals of nursing course. exclusion criteria: * who did not attend regularly during the sessions

Keywords: anxiety clinical decision-making simulation training nursing students
triheptanoin treatment trial for patients with adult polyglucosan body disease

Conditions: Adult Polyglucosan Body Disease; Glycogen Brancher Enzyme Deficiency; Glycogen Storage Disease Type IV

Summary: the purpose of the study is to determine if triheptanoin is an effective treatment for the symptoms of adult polyglucosan body disease.

adult polyglucosan disease is a progressive neurogenetic disorder characterized by neurogenic bladder, progressive difficulty with walking, and sensory abnormalities in the lower extremities which typically present in the 4th or 5th decade of life. the pathogenesis of the disease includes the accumulation of intracellular polyglucosan bodies (amylopectin-like polysaccharides) in the peripheral nerves as well as the central nervous system cells and is often associated with brancher enzyme deficiency which causes improper glycogen formation. it is hypothesized that decreased glycogen degradation leads to energy deficit in the nervous system cells. therefore, anaplerotic therapy may supply needed substrate to the citric acid cycle to correct the energy deficit. this intervention may slow, halt or reverse the progression of the disease, for which there is no effective treatment. the trial involves 18 subjects ingesting a diet supplemented with triheptanoin, a 7 carbon triglyceride or a placebo of vegetable oil at a dose of 1-2 g/kg/24 hours in a randomized crossover controlled double blind study. the study lasts one year with patients receiving triheptanoin for 6 mo and the placebo oil for 6 mo. safety monitoring includes urine organic acids and acyl carnitine profile.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of apbd by the presence of mutations of the gbe1 gene in both alleles or brancher enzyme deficiency * willing and able to travel to dallas tx * able to tolerate dietary oil * able to provide informed consent exclusion criteria: * intercurrent medical conditions that would confound the assessment of efficacy, such as hiv or diabetes * patients who are wheelchair bound * patients deemed unsuitable for the study by the investigator

Keywords: adult polyglucosan body disease (apbd) glycogen brancher enzyme (gbe1) deficiency
biochemical and histological comparison of nasal and auricular cartilage in the fetus and newborn with cleft lip carrier

Conditions: Newborn Cleft Lip and Slot Carrier

Summary: we seek to compare biochemically and histologically the nasal cartilage and ear in the newborn cleft lip and slot carrier in order to improve the quality of care and patient comfort after surgery of cheilorhinoplasty which is the primary treatment slots . the concentration of hyaluronic acid as well as in type 1 collagen and 3 are assayed by immunohistochemistry and study of mrna and then they are compared according to the type of cartilage. this comparison is done on nasal cartilage samples and atrial newborns holders of cleft lip and operated in the neonatal period. given the difficulty and constraint of time it takes to reach the 20 subjects of our study , we will also add to our population the stillborn babies before 25sa and newborns who die before the age of 28 days and having had an autopsy.


Eligibility criteria:
inclusion criteria: * infants aged 0 to 5 weeks with an isolated cleft lip and palate, that is to say non-syndromic, and that will be operated for cheilorhinoplasty neonatal, whose parents have read and understood the document information and accepted and signed informed consent, * children born without life before 25sa and whose parents have read and understood the information and accepted and signed informed consent for diagnostic purposes permission to autopsy and scientific purposes and / or therapeutic. * newborns who died before 28 days of life and whose parents have read and understood the information and accepted and signed informed consent for diagnostic purposes permission to autopsy and scientific purposes and / or therapeutic. * patients and relatives of patients who received clear information and having signed an informed consent, * patients benefiting from a health insurance plan exclusion criteria: * patient with no lip slots ( bike palate only or other tessier slot ) ) * patient having slots syndromic cleft lip * patient whose parents refuse entry into the study. * children born without life before 25sa * newborns who died after 28 days of life
myeloproliferative neoplasms (mpn) and covid-19

Conditions: Myeloproliferative Neoplasm; COVID

Summary: an increased risk of both venous and arterial thromboembolism was noted in reports from sars-cov-2-infected patients in china and has been confirmed in autopsy findings from patients who experienced sudden death. myeloproliferative neoplasms (mpns), which encompass polycythemia vera, essential thrombocythemia and primary myelofibrosis, are thrombophilic disorders with a natural propensity to thrombosis that is fuelled by the intrinsic activation of inflammatory cytokines. it therefore follows that an underlying diagnosis of mpn may increase the risk of worse clinical outcomes and death during periods of active covid-19 disease. this ambispective, observational study aims to elucidate the key factors which affect the clinical course of patients with mpn who develop covid-19 disease.

this is an european multicenter observational study that will include around 550 mpn patients with a confirmed diagnosis of covid-19 will be followed for at least one month. detailed information on the clinical characteristics of these patients and their disease outcomes will be retrospectively and prospectively collected in a specific ecrf, including mpn characteristics, treatment and comorbidities pre-covid-19, time of covid-19 diagnosis, drugs/device used for the treatment of covid-19, any change in mpn therapy, antithrombotic prophylaxis employed during the period of infection and - for hospitalised patients only - key blood and laboratory parameters. a particular focus will be on exploring final outcomes for patients in this study, most notably the incidence of fatal and non-fatal thrombotic events. statistical analyses will also be performed looking for any independent factors that can significantly predict patient outcomes after covid-19 diagnosis. ultimately, this project will provide important insights into disease severity and progression in patients with mpn and covid-19 and uncover the key clinical factors which drive outcomes and mortality. results may help clinicians better understand how patient characteristics and management decisions can impact on disease trajectory when mpn and covid-19 collide.

Eligibility criteria:
inclusion criteria: * age \> 18 years * confirmed diagnosed of mpn according to who criteria * diagnosis of covid-19 based by the positivity of oropharyngeal swab performed between 15 february 2020 up to 15 february 2022 * signed informed consent exclusion criteria: * none

Keywords: thrombosis
exploratory study of the digital therapeutics ct-155 in the treatment of people with schizophrenia

Conditions: Schizophrenia

Summary: ct-155 is a novel prescription digital therapeutic (pdt) being developed by click therapeutics, inc. (click) and boehringer ingelheim (bi) using an interactive, software-based intervention to treat schizophrenia

ct-155 is a novel prescription digital therapeutic (pdt) being developed by click therapeutics, inc. (click) and boehringer ingelheim (bi). ct-155 delivers an interactive, software-based intervention for schizophrenia. during a pdt development lifecycle, iterations of the pdt may be scientifically evaluated in a user population that is clinically representative of the intended patient population. data generated via this evaluation can be used to drive the modification and optimization of specific therapeutic components contained within a given pdt.

Eligibility criteria:
inclusion criteria: * 1. has outpatient treatment status of schizophrenia. * 2. is on a stable dose of antipsychotic medication(s) * 3. is the sole user of an iphone with iphone operating system (ios)13 or greater capabilities or a smart phone with an android operating system (os) 9 or greater capabilities. * 4. is the owner of, and has regular access to, an email address. * 5. has regular access to the internet via cellular data plan and/or wifi. * 6. willing and able to receive sms text messages on their smartphone and email messages, and understand how to use the downloaded study app. * 7. has stable housing and has remained at the same residence for at least 12 weeks prior to screening, with no anticipated housing changes during the duration of the study exclusion criteria: * 1. is currently treated with more than two antipsychotic medications. * 2. is currently treated with clozapine or haloperidol. * 3. has active prominent positive symptoms to preclude effective engagement in treatment for negative symptoms. * 4. is currently receiving or has received psychotherapy within 12 weeks prior to screening. * 5. meets either the international classification of diseases (icd-10) or dsm-5 criteria for diagnoses not under investigation. * 6. has post-traumatic stress disorder (ptsd), bipolar disorder, major depressive disorder, developmental disorders, or any prominent disorder. * 7. has substance or alcohol use disorder. * 8. currently needs or will likely require prohibited concomitant medications. * 9. is currently participating in another clinical study. * 10. prior participation in the ct-155-c-001 clinical study. * 11. has suicidal ideation or behavior.

Keywords: prescription digital therapeutics smartphone app schizophrenia